Pavel Jansa
- Chronic thromboembolic pulmonary hypertension: role of medical therapyBy Joanna Pepke-Zaba, Pavel Jansa, Nick H. Kim, Robert Naeije and Gerald SimonneauJoanna Pepke-Zaba*Pulmonary Vascular Diseases Unit, Papworth Hospital, Cambridge, UKPavel Jansa#Clinical Dept of Cardiology and Angiology, Charles University, 1st Faculty of Medicine, 2nd Medical Dept, Prague, Czech RepublicNick H. Kim¶Pulmonary Vascular Medicine, UC San Diego, La Jolla, CA, USARobert Naeije+Dept of Physiology, Université Libre de Bruxelles, Brussels, BelgiumGerald Simonneau§Centre National de Référence de l’Hypertension Artérielle Pulmonaire, Paris-Sud University, Paris, France
- Is 6-minute walk distance (6MWD) associated with long-term outcomes in pulmonary arterial hypertension (PAH)? Results from SERAPHINBy Marion Delcroix, Richard Channick, Nazzareno Galiè, Hossein-Ardeschir Ghofrani, Pavel Jansa, Franck-Olivier Le Brun, Sanjay Mehta, Loïc Perchenet, Tomás Pulido, B.K.S. Sastry, Olivier Sitbon, Rogério Souza, Adam Torbicki, Gérald Simonneau and Lewis RubinMarion Delcroix1Department of Pneumology, Gasthuisberg University Hospital, Leuven, BelgiumRichard Channick2Pulmonary and Critical Care, Massachusetts General Hospital, Boston, United StatesNazzareno Galiè3Institute of Cardiology, University of Bologna, Bologna, ItalyHossein-Ardeschir Ghofrani4Pulmonary Hypertension Division, Department of Internal Medicine II, University Hospital Giessen, Giessen, GermanyPavel Jansa5Clinical Department of Cardiology and Angiology, 1st Faculty of Medicine, 2nd Medical Department, Charles University, Prague, Czech RepublicFranck-Olivier Le Brun6Actelion Pharmaceuticals Ltd, Actelion Pharmaceuticals Ltd, Allschwil, SwitzerlandSanjay Mehta7Division of Respirology, Department of Medicine, London Health Sciences Centre - Victoria Hospital, Western University, London, CanadaLoïc Perchenet6Actelion Pharmaceuticals Ltd, Actelion Pharmaceuticals Ltd, Allschwil, SwitzerlandTomás Pulido8Cardiopulmonary Department, The National Institute of Cardiology, Mexico City, MexicoB.K.S. Sastry9Department of Cardiology, CARE Hospitals, Hyderabad, IndiaOlivier Sitbon10CHU De Bicêtre, Université Paris-Sud, Le Kremlin Bicêtre, FranceRogério Souza11Pulmonary Department, Heart Institute, University of São Paulo Medical School, São Paulo, BrazilAdam Torbicki12Department of Pulmonary Circulation and Thromboembolic Diseases, Center of Postgraduate Medical Education, ECZ-Otwock, PolandGérald Simonneau10CHU De Bicêtre, Université Paris-Sud, Le Kremlin Bicêtre, FranceLewis Rubin13Division of Pulmonary & Critical Care Medicine, University of California, San Diego, United States
- Effect of macitentan on haemodynamics in SERAPHIN, a randomised controlled trial in pulmonary arterial hypertension (PAH)By Olivier Sitbon, Richard Channick, Marion Delcroix, Nazzareno Galiè, Hossein-Ardeschir Ghofrani, Pavel Jansa, Franck-Olivier Le Brun, Sanjay Mehta, Loïc Perchenet, Tomás Pulido, B.K.S. Sastry, Rogério Souza, Adam Torbicki, Lewis Rubin and Gérald SimonneauOlivier Sitbon1CHU De Bicêtre, Université Paris-Sud, Le Kremlin Bicêtre, FranceRichard Channick2Pulmonary and Critical Care, Massachusetts General Hospital, Boston, United StatesMarion Delcroix3Department of Pneumology, Gasthuisberg University Hospital, Leuven, BelgiumNazzareno Galiè4Institute of Cardiology, University of Bologna, Bologna, ItalyHossein-Ardeschir Ghofrani5Pulmonary Hypertension Division, Department of Internal Medicine II, University Hospital Giessen, Giessen, GermanyPavel Jansa6Clinical Department of Cardiology and Angiology, 1st Faculty of Medicine, 2nd Medical Department, Charles University, Prague, Czech RepublicFranck-Olivier Le Brun7Actelion Pharmaceuticals Ltd, Actelion Pharmaceuticals Ltd, Allschwil, SwitzerlandSanjay Mehta8Division of Respirology, Department of Medicine, London Health Sciences Centre - Victoria Hospital, Western University, London, CanadaLoïc Perchenet7Actelion Pharmaceuticals Ltd, Actelion Pharmaceuticals Ltd, Allschwil, SwitzerlandTomás Pulido9Cardiopulmonary Department, The National Institute of Cardiology, Mexico City, MexicoB.K.S. Sastry10Department of Cardiology, CARE Hospitals, Hyderabad, IndiaRogério Souza11Pulmonary Department, Heart Institute, University of São Paulo Medical School, São Paulo, BrazilAdam Torbicki12Department of Pulmonary Circulation and Thromboembolic Diseases, Center of Postgraduate Medical Education, ECZ-Otwock, PolandLewis Rubin13Division of Pulmonary & Critical Care Medicine, University of California, San Diego, United StatesGérald Simonneau1CHU De Bicêtre, Université Paris-Sud, Le Kremlin Bicêtre, France
- An interim analysis of the phase III riociguat long-term extension study in CTEPH (CHEST-2)By Gerald Simonneau, Andrea M. D'Armini, Hossein-Ardeschir Ghofrani, Friedrich Grimminger, Marius M. Hoeper, Pavel Jansa, Nick H. Kim, Chen Wang, Martin R. Wilkins, Arno Fritsch, Neil Davie, Gerrit Weimann and Eckhard MayerGerald Simonneau1Univ. Paris-Sud; Inserm U999; AP-HP, Hôpital Bicêtre, Service De Pneumologie, Le Kremlin-Bicêtre, FranceAndrea M. D'Armini2Division of Cardiac Surgery, IRCCS Policlinico San Matteo, University of Pavia School of Medicine, Pavia, ItalyHossein-Ardeschir Ghofrani3Department of Internal Medicine, University of Giessen and Marburg Lung Center, Member of the German Center of Lung Research (DZL), Giessen, GermanyFriedrich Grimminger3Department of Internal Medicine, University of Giessen and Marburg Lung Center, Member of the German Center of Lung Research (DZL), Giessen, GermanyMarius M. Hoeper4Clinic for Respiratory Medicine, Hannover Medical School, Hannover, GermanyPavel Jansa5Clinical Department of Cardiology and Angiology, First Faculty of Medicine and General Teaching Hospital, Prague, Czech RepublicNick H. Kim6Division of Pulmonary and Critical Care Medicine, UCSD School of Medicine, San Diego, United StatesChen Wang7Department of Respiratory Medicine, Beijing Institute of Respiratory Medicine, Beijing Chao Yang Hospital, Capital Medical University, Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing, ChinaMartin R. Wilkins8Centre for Pharmacology and Therapeutics, Division of Experimental Medicine, Imperial College London, Hammersmith Hospital, London, United KingdomArno Fritsch9Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyNeil Davie9Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyGerrit Weimann9Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyEckhard Mayer10Department of Thoracic Surgery, Kerckhoff Heart and Lung Center, Bad Nauheim, Germany
- Effect of macitentan on morbidity and mortality in pulmonary arterial hypertension: A randomised controlled trial (SERAPHIN)By Hossein-Ardeschir Ghofrani, Richard Channick, Marion Delcroix, Nazzareno Galiè, Pavel Jansa, Franck-Olivier Le Brun, Sanjay Mehta, Camilla Mittelholzer, Tomás Pulido, B.K.S. Sastry, Olivier Sitbon, Rogério Souza, Adam Torbicki, Lewis Rubin and Gérald SimonneauHossein-Ardeschir Ghofrani1Pulmonary Hypertension Division, Department of Internal Medicine II, University Hospital Giessen, Giessen, GermanyRichard Channick2Pulmonary and Critical Care, Massachusetts General Hospital, Boston, United StatesMarion Delcroix3Department of Pneumology, Gasthuisberg University Hospital, Leuven, BelgiumNazzareno Galiè4Institute of Cardiology, University of Bologna, Bologna, ItalyPavel Jansa5Clinical Department of Cardiology and Angiology, 1st Faculty of Medicine, 2nd Medical Department, Charles University, Prague, Czech RepublicFranck-Olivier Le Brun6Actelion Pharmaceuticals Ltd, Actelion Pharmaceuticals Ltd, Allschwil, SwitzerlandSanjay Mehta7Division of Respirology, Department of Medicine, London Health Sciences Centre - Victoria Hospital, Western University, London, CanadaCamilla Mittelholzer6Actelion Pharmaceuticals Ltd, Actelion Pharmaceuticals Ltd, Allschwil, SwitzerlandTomás Pulido8Cardiopulmonary Department, The National Institute of Cardiology, Mexico City, MexicoB.K.S. Sastry9Department of Cardiology, CARE Hospitals, Hyderabad, IndiaOlivier Sitbon10CHU De Bicêtre, Université Paris-Sud, Le Kremlin Bicêtre, FranceRogério Souza11Pulmonary Department, Heart Institute, University of São Paulo Medical School, São Paulo, BrazilAdam Torbicki12Department of Pulmonary Circulation and Thromboembolic Diseases, Center of Postgraduate Medical Education, ECZ-Otwock, PolandLewis Rubin13Division of Pulmonary & Critical Care Medicine, University of California, San Diego, United StatesGérald Simonneau10CHU De Bicêtre, Université Paris-Sud, Le Kremlin Bicêtre, France
- Impact of macitentan on the health-related quality of life (HRQoL) in pulmonary arterial hypertension (PAH): Results from a long-term randomised controlled trialBy Pavel Jansa, Richard Channick, Marion Delcroix, Nazzareno Galiè, Hossein-Ardeschir Ghofrani, Elke Hunche, Sanjay Mehta, Camilla Mittelholzer, Tomás Pulido, B.K.S. Sastry, Olivier Sitbon, Rogério Souza, Adam Torbicki, Gérald Simonneau and Lewis RubinPavel Jansa1Clinical Department of Cardiology and Angiology, 1st Faculty of Medicine, 2nd Medical Department, Charles University, Prague, Czech RepublicRichard Channick2Pulmonary and Critical Care, Massachusetts General Hospital, Boston, United StatesMarion Delcroix3Department of Pneumology, Gasthuisberg University Hospital, Leuven, BelgiumNazzareno Galiè4Institute of Cardiology, University of Bologna, Bologna, ItalyHossein-Ardeschir Ghofrani5Pulmonary Hypertension Division, Department of Internal Medicine II, University Hospital Giessen, Giessen, GermanyElke Hunche6Actelion Pharmaceuticals Ltd, Actelion Pharmaceuticals Ltd, Allschwil, SwitzerlandSanjay Mehta7Division of Respirology, Department of Medicine, London Health Sciences Centre - Victoria Hospital, Western University, London, CanadaCamilla Mittelholzer6Actelion Pharmaceuticals Ltd, Actelion Pharmaceuticals Ltd, Allschwil, SwitzerlandTomás Pulido8Cardiopulmonary Department, The National Institute of Cardiology, Mexico City, MexicoB.K.S. Sastry9Department of Cardiology, CARE Hospitals, Hyderabad, IndiaOlivier Sitbon10CHU De Bicêtre, Université Paris-Sud, Le Kremlin Bicêtre, FranceRogério Souza11Pulmonary Department, Heart Institute, University of São Paulo Medical School, São Paulo, BrazilAdam Torbicki12Department of Pulmonary Circulation and Thromboembolic Diseases, Center of Postgraduate Medical Education, ECZ-Otwock, PolandGérald Simonneau10CHU De Bicêtre, Université Paris-Sud, Le Kremlin Bicêtre, FranceLewis Rubin13Division of Pulmonary & Critical Care Medicine, University of California, San Diego, United States
- Chronic Thromboembolic Pulmonary Hypertension: Role of medical therapyBy Joanna Pepke-Zaba, Pavel Jansa, Nick H. Kim, Robert Naejie and Gerald SimonneauArticle | Published in 2012 in European Respiratory JournalJoanna Pepke-Zaba*Pulmonary Vascular Diseases Unit, Papworth Hospital, Cambridge, UKPavel Jansa#Charles University, 1st Faculty of Medicine, 2nd Medical Dept, Clinical Dept of Cardiology and Angiology, Prague, Czech RepublicNick H. Kim¶UC San Diego, Pulmonary Vascular Medicine, La Jolla, California, USARobert Naejie+Dept of Physiology, Université Libre de Bruxelles, Brussels, BelgiumGerald Simonneau§Centre National de Référence de l’Hypertension Artérielle Pulmonaire, Paris-Sud University, Paris, France
- Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2)By Gérald Simonneau, Andrea M. D’Armini, Hossein-Ardeschir Ghofrani, Friedrich Grimminger, Marius M. Hoeper, Pavel Jansa, Nick H. Kim, Chen Wang, Martin Wilkins, Arno Fritsch, Neil Davie, Pablo Colorado and Eckhard MayerArticle | Published in 2014 in European Respiratory JournalGérald Simonneau1Assistance Publique–Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Laboratoire d’Excellence en Recherche sur le Médicament et Innovation Thérapeutique, and INSERM Unité 999, Le Kremlin–Bicêtre, FranceAndrea M. D’Armini2Division of Cardiothoracic Surgery, Foundation “I.R.C.C.S. Policlinico San Matteo”, University of Pavia School of Medicine, Pavia, ItalyHossein-Ardeschir Ghofrani3University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany, and Member of the German Center of Lung Research (DZL)4Dept of Medicine, Imperial College London, London, UKFriedrich Grimminger3University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany, and Member of the German Center of Lung Research (DZL)Marius M. Hoeper5Clinic for Respiratory Medicine, Hannover Medical School, Hannover, Germany, and Member of the German Center of Lung Research (DZL)Pavel Jansa6Clinical Dept of Cardiology and Angiology, First Faculty of Medicine and General Teaching Hospital, Prague, Czech RepublicNick H. Kim7Division of Pulmonary and Critical Care Medicine, School of Medicine, University of California San Diego, San Diego, CA, USAChen Wang8Beijing Institute of Respiratory Medicine, Beijing Chao Yang Hospital, Dept of Respiratory Medicine, Capital Medical University, Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing, ChinaMartin Wilkins9National Institute for Health Research/Wellcome Trust Imperial Clinical Research Facility, Imperial Centre for Translational and Experimental Medicine, Imperial College London, London, UKArno Fritsch10Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyNeil Davie10Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyPablo Colorado11Global Clinical Development, Bayer HealthCare Pharmaceuticals, Barcelona, SpainEckhard Mayer12Kerckhoff Heart and Lung Center, Bad Nauheim, Germany
- Macitentan reduces the risk of morbidity and mortality irrespective of the presence or absence of right ventricular (RV) impairment: Results from the randomised SERAPHIN trial in pulmonary arterial hypertension (PAH)By Olivier Sitbon, Richard N. Channick, Marion Delcroix, Hossein-Ardeschir Ghofrani, Pavel Jansa, Franck-Olivier Le Brun, Sanjay Mehta, Loïc Perchenet, Tomás Pulido, Lewis J. Rubin, B.K.S. Sastry, Gérald Simonneau, Rogério Souza, Adam Torbicki and Nazzareno GalièOlivier Sitbon1Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Le Kremlin-Bicêtre, FranceRichard N. Channick2Pulmonary and Critical Care, Massachusetts General Hospital, Boston, MA,Marion Delcroix3Department of Pneumology, Gasthuisberg University Hospital, Leuven, BelgiumHossein-Ardeschir Ghofrani4University of Giessen and Marburg Lung Center, German Center of Lung Research (DZL), Giessen, GermanyPavel Jansa5Clinical Department of Cardiology and Angiology, Charles University, Prague, Czech RepublicFranck-Olivier Le Brun6Actelion Pharmaceuticals Ltd, Actelion Pharmaceuticals Ltd, Allschwil, SwitzerlandSanjay Mehta7Division of Respirology, Department of Medicine, London Health Sciences Centre – Victoria Hospital, Western University, London, ON, CanadaLoïc Perchenet6Actelion Pharmaceuticals Ltd, Actelion Pharmaceuticals Ltd, Allschwil, SwitzerlandTomás Pulido8CardioPulmonary Department, Ignacio Chávez National Heart Institute, Mexico City, MexicoLewis J. Rubin9Division of Pulmonary and Critical Care Medicine, University of California, San Diego Medical School, San Diego, CA,B.K.S. Sastry10Department of Cardiology, CARE Hospitals, Hyderabad, IndiaGérald Simonneau1Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Le Kremlin-Bicêtre, FranceRogério Souza11Pulmonary Department, Heart Institute, University of São Paulo Medical School, São Paulo, BrazilAdam Torbicki12Department of Pulmonary Circulation and Thromboembolic Diseases, Center of Postgraduate Medical Education, ECZ-Otwock, Otwock, PolandNazzareno Galiè13Department of Experimental, Diagnostic and Specialty Medicine-DIMES, Bologna University Hospital, Bologna, Italy
- Late-breaking abstract: Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 2-year results from the CHEST-2 long-term extensionBy Gérald Simonneau, Andrea M. D'Armini, Hossein-Ardeschir Ghofrani, Friedrich Grimminger, Marius M. Hoeper, Pavel Jansa, Nick H. Kim, Chen Wang, Martin Wilkins, Arno Fritsch, Neil Davie, Pablo Colorado and Eckhard MayerGérald Simonneau1Assistance Publique–Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, and INSERM Unité 999, Le Kremlin–Bicêtre, FranceAndrea M. D'Armini2Division of Cardiothoracic Surgery, Foundation "I.R.C.C.S. Policlinico San Matteo", University of Pavia School of Medicine, Pavia, ItalyHossein-Ardeschir Ghofrani3Department of Internal Medicine, University of Giessen and Marburg Lung Center (UGMLC), member of the German Center of Lung Research (DZL), Giessen, Germany4Dept of Medicine, Imperial College London, London, United KingdomFriedrich Grimminger3Department of Internal Medicine, University of Giessen and Marburg Lung Center (UGMLC), member of the German Center of Lung Research (DZL), Giessen, GermanyMarius M. Hoeper5Clinic for Respiratory Medicine, Hannover Medical School, Member of the German Center of Lung Research (DZL), Hannover, GermanyPavel Jansa6Clinical Dept of Cardiology and Angiology, First Faculty of Medicine and General Teaching Hospital, Prague, Czech RepublicNick H. Kim7Division of Pulmonary and Critical Care Medicine, School of Medicine, University of California, San Diego, La Jolla,Chen Wang8Beijing Institute of Respiratory Medicine, Beijing Chao Yang Hospital, Dept of Respiratory Medicine, Capital Medical University, Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing, ChinaMartin Wilkins9National Institute for Health Research/Wellcome Trust Imperial Clinical Research Facility, Imperial Centre for Translational and Experimental Medicine, Imperial College London, London, United KingdomArno Fritsch10Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyNeil Davie10Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyPablo Colorado11Global Clinical Development, Bayer HealthCare Pharmaceuticals, Barcelona, SpainEckhard Mayer12Department of Thoracic Surgery, Kerckhoff Heart and Lung Center, Bad Nauheim, Germany
- Effects of riociguat in patients with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following pulmonary endarterectomy (PEA)By Eckhard Mayer, Andrzej Biederman, Andrea M. D'Armini, Ekkehard Grünig, Pavel Jansa, David P. Jenkins, Nick H. Kim, Walter Klepetko, Jaroslav Lindner, Michael M. Madani, Chen Wang, Neil Davie, Arno Fritsch and Hossein-Ardeschir GhofraniEckhard Mayer1Department of Thoracic Surgery, Kerckhoff Heart and Lung Center, Bad Nauheim, GermanyAndrzej Biederman2Department of Cardiac Surgery, Alendort Hospital, Warsaw, PolandAndrea M. D'Armini3Division of Cardiothoracic Surgery, Foundation "I.R.C.C.S. Policlinico San Matteo", University of Pavia School of Medicine, Pavia, ItalyEkkehard Grünig4Centre for Pulmonary Hypertension, Thoraxclinic, University Hospital Heidelberg, Heidelberg, GermanyPavel Jansa5Clinical Department of Cardiology and Angiology, First Faculty of Medicine and General Teaching Hospital, Prague, Czech RepublicDavid P. Jenkins6National Pulmonary Endarterectomy Service, Papworth Hospital, Cambridge, United KingdomNick H. Kim7Division of Pulmonary and Critical Care Medicine, UCSD School of Medicine, San Diego, CA,Walter Klepetko8Department of Cardiothoracic Surgery, Vienna General Hospital, Medical University of Vienna, Vienna, AustriaJaroslav Lindner92nd Surgical Department – Clinical Department of Cardiovascular Surgery, Charles University Prague, First Faculty of Medicine and General Teaching Hospital, Prague, Czech RepublicMichael M. Madani10Division of Cardiovascular and Thoracic Surgery, University of California San Diego Medical Center, San Diego, CA,Chen Wang11Beijing Institute of Respiratory Medicine, Beijing Chao Yang Hospital, Department of Respiratory Medicine, Capital Medical University, Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing, ChinaNeil Davie12Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyArno Fritsch12Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyHossein-Ardeschir Ghofrani13Department of Internal Medicine, University of Giessen and Marburg Lung Center (UGMLC), Member of the German Center of Lung Research (DZL), Giessen, Germany
- Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2)By Gérald Simonneau, Andrea M. D’Armini, Hossein-Ardeschir Ghofrani, Friedrich Grimminger, Marius M. Hoeper, Pavel Jansa, Nick H. Kim, Chen Wang, Martin R. Wilkins, Arno Fritsch, Neil Davie, Pablo Colorado and Eckhard MayerGérald Simonneau1Assistance Publique–Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Laboratoire d’Excellence en Recherche sur le Médicament et Innovation Thérapeutique, and INSERM Unité 999, Le Kremlin–Bicêtre, FranceAndrea M. D’Armini2Division of Cardiothoracic Surgery, Foundation “I.R.C.C.S. Policlinico San Matteo”, University of Pavia School of Medicine, Pavia, ItalyHossein-Ardeschir Ghofrani3University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany, and Member of the German Center of Lung Research (DZL)4Dept of Medicine, Imperial College London, London, UKFriedrich Grimminger3University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany, and Member of the German Center of Lung Research (DZL)Marius M. Hoeper5Clinic for Respiratory Medicine, Hannover Medical School, Hannover, Germany, and Member of the German Center of Lung Research (DZL)Pavel Jansa6Clinical Dept of Cardiology and Angiology, First Faculty of Medicine and General Teaching Hospital, Prague, Czech RepublicNick H. Kim7Division of Pulmonary and Critical Care Medicine, School of Medicine, University of California San Diego, San Diego, CA, USAChen Wang8Beijing Institute of Respiratory Medicine, Beijing Chao Yang Hospital, Dept of Respiratory Medicine, Capital Medical University, Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing, ChinaMartin R. Wilkins9National Institute for Health Research/Wellcome Trust Imperial Clinical Research Facility, Imperial Centre for Translational and Experimental Medicine, Imperial College London, London, UKArno Fritsch10Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyNeil Davie10Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyPablo Colorado11Global Clinical Development, Bayer HealthCare Pharmaceuticals, Barcelona, SpainEckhard Mayer12Kerckhoff Heart and Lung Center, Bad Nauheim, Germany
- Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHINBy Gérald Simonneau, Richard N. Channick, Marion Delcroix, Nazzareno Galiè, Hossein-Ardeschir Ghofrani, Pavel Jansa, Franck-Olivier Le Brun, Sanjay Mehta, Loic Perchenet, Tomás Pulido, B.K.S. Sastry, Olivier Sitbon, Rogério Souza, Adam Torbicki and Lewis J. RubinArticle | Published in 2015 in European Respiratory JournalGérald Simonneau1Assistance Publique–Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Le Kremlin–Bicêtre, France2Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, Le Kremlin–Bicêtre, France3INSERM U-999, Centre chirurgical Marie Lannelongue, Le Plessis Robinson, FranceRichard N. Channick4Pulmonary and Critical Care, Massachusetts General Hospital, Boston, MA, USAMarion Delcroix5Department of Pneumology, Gasthuisberg University Hospital, Leuven, BelgiumNazzareno Galiè6Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Bologna University Hospital, Bologna, ItalyHossein-Ardeschir Ghofrani7University of Giessen and Marburg Lung Center, Giessen, Germany8Member of the German Center of Lung Research (DZL), Giessen, Germany9Department of Medicine, Imperial College London, London, UKPavel Jansa10Clinical Department of Cardiology and Angiology, 1st Faculty of Medicine, 2nd Medical Department, Charles University, Prague, Czech RepublicFranck-Olivier Le Brun11Actelion Pharmaceuticals Ltd, Allschwil, SwitzerlandSanjay Mehta12Division of Respirology, Department of Medicine, London Health Sciences Centre – Victoria Hospital, Western University, London, ON, CanadaLoic Perchenet11Actelion Pharmaceuticals Ltd, Allschwil, SwitzerlandTomás Pulido13Cardiopulmonary Department, Ignacio Chávez National Heart Institute, Mexico City, MexicoB.K.S. Sastry14Department of Cardiology, CARE Hospitals, Hyderabad, IndiaOlivier Sitbon1Assistance Publique–Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Le Kremlin–Bicêtre, France2Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, Le Kremlin–Bicêtre, France3INSERM U-999, Centre chirurgical Marie Lannelongue, Le Plessis Robinson, FranceRogério Souza15Pulmonary Department, Heart Institute, University of São Paulo Medical School, São Paulo, BrazilAdam Torbicki16Department of Pulmonary Circulation and Thromboembolic Diseases, Center of Postgraduate Medical Education, ECZ-Otwock, Otwock, PolandLewis J. Rubin17Division of Pulmonary and Critical Care Medicine, University of California, San Diego Medical School, San Diego, CA, USA
- Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHINBy Gérald Simonneau, Richard N. Channick, Marion Delcroix, Nazzareno Galiè, Hossein-Ardeschir Ghofrani, Pavel Jansa, Franck-Olivier Le Brun, Sanjay Mehta, Loic Perchenet, Tomás Pulido, B.K.S. Sastry, Olivier Sitbon, Rogério Souza, Adam Torbicki and Lewis J. RubinGérald Simonneau1Assistance Publique–Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Le Kremlin–Bicêtre, France2Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, Le Kremlin–Bicêtre, France3INSERM U-999, Centre chirurgical Marie Lannelongue, Le Plessis Robinson, FranceRichard N. Channick4Pulmonary and Critical Care, Massachusetts General Hospital, Boston, MA, USAMarion Delcroix5Department of Pneumology, Gasthuisberg University Hospital, Leuven, BelgiumNazzareno Galiè6Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Bologna University Hospital, Bologna, ItalyHossein-Ardeschir Ghofrani7University of Giessen and Marburg Lung Center, Giessen, Germany8Member of the German Center of Lung Research (DZL), Giessen, Germany9Department of Medicine, Imperial College London, London, UKPavel Jansa10Clinical Department of Cardiology and Angiology, 1st Faculty of Medicine, 2nd Medical Department, Charles University, Prague, Czech RepublicFranck-Olivier Le Brun11Actelion Pharmaceuticals Ltd, Allschwil, SwitzerlandSanjay Mehta12Division of Respirology, Department of Medicine, London Health Sciences Centre – Victoria Hospital, Western University, London, ON, CanadaLoic Perchenet11Actelion Pharmaceuticals Ltd, Allschwil, SwitzerlandTomás Pulido13Cardiopulmonary Department, Ignacio Chávez National Heart Institute, Mexico City, MexicoB.K.S. Sastry14Department of Cardiology, CARE Hospitals, Hyderabad, IndiaOlivier Sitbon1Assistance Publique–Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Le Kremlin–Bicêtre, France2Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, Le Kremlin–Bicêtre, France3INSERM U-999, Centre chirurgical Marie Lannelongue, Le Plessis Robinson, FranceRogério Souza15Pulmonary Department, Heart Institute, University of São Paulo Medical School, São Paulo, BrazilAdam Torbicki16Department of Pulmonary Circulation and Thromboembolic Diseases, Center of Postgraduate Medical Education, ECZ-Otwock, Otwock, PolandLewis J. Rubin17Division of Pulmonary and Critical Care Medicine, University of California, San Diego Medical School, San Diego, CA, USA
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.